Medicure Inc (MCUJF) 4.7800 $MCUJF FDA Approves
Post# of 273318
Posted On: 09/26/2016 3:13:48 AM
Medicure Inc (MCUJF) 4.7800 $MCUJF
FDA Approves New AGGRASTAT® Product Format
PR Newswire - Thu Sep 01, 7:00AM CDT
Bolus Vial to Improve Delivery Convenience
MPH.VN: 6.420 (+0.170)
Medicure Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 10, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2016.
MPH.VN: 6.420 (+0.170)
Medicure to Announce Q2 2016 Financial Results on August 10, 2016
PR Newswire - Wed Aug 03, 3:12PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the second quarter ended June 30, 2016 after market close on Wednesday, August 10, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, August 11 2016, at 7:30 AM Central Time (8:30 AM Eastern Time).
MPH.VN: 6.420 (+0.170)
Medicure Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2016.
MPH.VN: 6.420 (+0.170)
Medicure Files Application for New AGGRASTAT® Product Format
CNW Group - Wed May 11, 7:00AM CDT
Expects to Launch Bolus Vial in Q3 2016
MPH.VN: 6.420 (+0.170)
Medicure Announces Departure of President and Chief Operating Officer
PR Newswire - Mon May 09, 6:00PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Dawson Reimer, has been terminated, effective immediately. "I and the entire Board of Directors thank Dawson for his commitment and dedication throughout his years of service with Medicure. We wish him all the best in his new endeavours," said Dr. Albert Friesen, Board Chair and CEO of Medicure Inc.
MPH.VN: 6.420 (+0.170)
Medicure to Announce Q1 2016 Financial Results on May 11, 2016
PR Newswire - Wed May 04, 6:00PM CDT
Medicure Inc. ("Medicure" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2016 after market close on Wednesday, May 11, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, May 12 2016, at 7:30 AM Central Time (8:30 AM Eastern Time).
MPH.VN: 6.420 (+0.170)
Medicure to present at Cantech Investment Conference
PR Newswire - Thu Jan 21, 10:44AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will present at the 2016 Cantech Investment Conference on January 26th in Toronto.
MPH.VN: 6.420 (+0.170)
Medicure Announces Preliminary Revenue For Fiscal 2015
PR Newswire - Mon Jan 11, 8:30AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported unaudited net revenue for the 2015 fourth quarter and full fiscal year. All amounts referenced herein are in Canadian dollars.
MPH.VN: 6.420 (+0.170)
Medicure announces ANDA collaboration with Apicore
PR Newswire - Wed Jan 06, 7:00AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore", a leading-edge manufacturer of generic active pharmaceutical ingredients ("API's".
MPH.VN: 6.420 (+0.170)
Medicure Announces PDUFA Action Date for New Aggrastat Indication
PR Newswire - Wed Dec 02, 9:48AM CST
Medicure Inc. ("Medicure" or the "Company" (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA" has assigned a Prescription Drug User Fee Act ("PDUFA" action date of July 10, 2016, for completing its review of the AGGRASTAT (tirofiban HCl) supplemental New Drug Application ("sNDA" submitted by the Company. The filing of the sNDA was previously announced on September 10, 2015. If approved, the indication statement for AGGRASTAT would be expanded to include the treatment of patients presenting with ST segment elevation myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI).
MPH.VN: 6.420 (+0.170)
Medicure Announces Grant of Stock Options
CNW Group - Wed Nov 25, 4:55PM CST
Medicure Inc. (the "Company" (TSXV:MPH, OTC:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 168,000 stock options to certain employees and consultants of the Company pursuant to the Company's Stock Option Plan. These stock options are set to expire on the fifth anniversary of the date of grant. All of the stock options were issued at an exercise price of $3.90 per share. The stock options are subject to the approval of the TSX Venture Exchange.
MPH.VN: 6.420 (+0.170)
FDA Approves New AGGRASTAT® Product Format
PR Newswire - Thu Sep 01, 7:00AM CDT
Bolus Vial to Improve Delivery Convenience
MPH.VN: 6.420 (+0.170)
Medicure Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 10, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2016. MPH.VN: 6.420 (+0.170)
Medicure to Announce Q2 2016 Financial Results on August 10, 2016
PR Newswire - Wed Aug 03, 3:12PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the second quarter ended June 30, 2016 after market close on Wednesday, August 10, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, August 11 2016, at 7:30 AM Central Time (8:30 AM Eastern Time). MPH.VN: 6.420 (+0.170)
Medicure Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 11, 4:00PM CDT
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTCQB:MCUJF), a specialty pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2016. MPH.VN: 6.420 (+0.170)
Medicure Files Application for New AGGRASTAT® Product Format
CNW Group - Wed May 11, 7:00AM CDT
Expects to Launch Bolus Vial in Q3 2016
MPH.VN: 6.420 (+0.170)
Medicure Announces Departure of President and Chief Operating Officer
PR Newswire - Mon May 09, 6:00PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company today announced that the employment agreement with President and Chief Operating Officer, Dawson Reimer, has been terminated, effective immediately. "I and the entire Board of Directors thank Dawson for his commitment and dedication throughout his years of service with Medicure. We wish him all the best in his new endeavours," said Dr. Albert Friesen, Board Chair and CEO of Medicure Inc. MPH.VN: 6.420 (+0.170)
Medicure to Announce Q1 2016 Financial Results on May 11, 2016
PR Newswire - Wed May 04, 6:00PM CDT
Medicure Inc. ("Medicure"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2016 after market close on Wednesday, May 11, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, May 12 2016, at 7:30 AM Central Time (8:30 AM Eastern Time). MPH.VN: 6.420 (+0.170)
Medicure to present at Cantech Investment Conference
PR Newswire - Thu Jan 21, 10:44AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that it will present at the 2016 Cantech Investment Conference on January 26th in Toronto. MPH.VN: 6.420 (+0.170)
Medicure Announces Preliminary Revenue For Fiscal 2015
PR Newswire - Mon Jan 11, 8:30AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today reported unaudited net revenue for the 2015 fourth quarter and full fiscal year. All amounts referenced herein are in Canadian dollars. MPH.VN: 6.420 (+0.170)
Medicure announces ANDA collaboration with Apicore
PR Newswire - Wed Jan 06, 7:00AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates "Apicore", a leading-edge manufacturer of generic active pharmaceutical ingredients ("API's". MPH.VN: 6.420 (+0.170)
Medicure Announces PDUFA Action Date for New Aggrastat Indication
PR Newswire - Wed Dec 02, 9:48AM CST
Medicure Inc. ("Medicure" or the "Company"
(TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA" has assigned a Prescription Drug User Fee Act ("PDUFA" action date of July 10, 2016, for completing its review of the AGGRASTAT (tirofiban HCl) supplemental New Drug Application ("sNDA" submitted by the Company. The filing of the sNDA was previously announced on September 10, 2015. If approved, the indication statement for AGGRASTAT would be expanded to include the treatment of patients presenting with ST segment elevation myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI). MPH.VN: 6.420 (+0.170)
Medicure Announces Grant of Stock Options
CNW Group - Wed Nov 25, 4:55PM CST
Medicure Inc. (the "Company"
(TSXV:MPH, OTC:MCUJF) announces today that its Board of Directors has approved the grant of an aggregate of 168,000 stock options to certain employees and consultants of the Company pursuant to the Company's Stock Option Plan. These stock options are set to expire on the fifth anniversary of the date of grant. All of the stock options were issued at an exercise price of $3.90 per share. The stock options are subject to the approval of the TSX Venture Exchange. MPH.VN: 6.420 (+0.170)
(0)
(0)